Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Takeshi Miyao"'
Autor:
Nishimoto, Koshiro, Kenichi, Nakajima, Masafumi, Oyama, Go, Kaneko, Satoru, Takahashi, Hideyasu, Matsuyama, Hiroaki, Shiina, Tomohiko, Ichikawa, Hiroyuki, Horikoshi, Katsuyoshi, Hashine, Yutaka, Sugiyama, Takeshi, Miyao, Manabu, Kamiyama, Kenichi, Harada, Akito, Ito, Atsushi, Mizokami
Publikováno v:
International Journal of Urology. 29:1477-1487
Novel androgen receptor axis-targeted agents (ARATAs) have been developed for mCRPC and improved overall survival (OS). Here, we aimed to find predictors who will receive the greatest benefits from ARATAs.We previously performed a multicenter study t
Autor:
Taiki, Kamijima, Hiroshi, Yaegashi, Atsushi, Mizokami, Kenichi, Nakajima, Hideyasu, Matsuyama, Tomohiko, Ichikawa, Koshiro, Nishimoto, Satoru, Takahashi, Hiroaki, Shiina, Hiroyuki, Horikoshi, Katsuyoshi, Hashine, Yutaka, Sugiyama, Takeshi, Miyao, Manabu, Kamiyama, Kenichi, Harada, Akito, Ito, Hideki, Enokida
Publikováno v:
Anticancer Research. 42:3099-3108
This study aimed to evaluate the therapeutic benefit of novel androgen receptor-targeted agents (ARTAs) in castration-resistant prostate cancer (CRPC) with bone metastases in Japan.In followup to our prospective observational study (PROSTAT-BSI) from
Publikováno v:
Japanese Journal of Complementary and Alternative Medicine. 19:15-21
Autor:
Kyoko Baba, Yoshiyuki Miyazawa, Takeshi Miyao, Daisuke Oka, Hiroshi Nakayama, Yasuhiro Shibata, Masanori Aoki, Sota Kurihara, Ryo Ohki, Kazuhiro Suzuki, Takuma Hayashi, Akira Ohtsu, Yoshitaka Sekine
Publikováno v:
Nihon Toseki Igakkai Zasshi. 54:155-158
Autor:
Kazunori Hattori, Takatsugu Okegawa, Yoshitaka Sekine, Masashi Nomura, Hiroshi Matsui, Hiroshi Nakayama, Kazuhiro Suzuki, Yasuhiro Shibata, Kenzo Okauchi, Sota Kurihara, Takeshi Miyao, Takahiro Syuutou, Yoshiyuki Miyazawa, Hidekazu Koike
Publikováno v:
The Kitakanto Medical Journal. 70:83-94
Autor:
Kazuhiro Suzuki, Seiji Arai, Yutaka Takezawa, Takeshi Miyao, Daisuke Oka, Tomoyuki Takei, O. Haruyuki, Yoshiyuki Miyazawa, Tetsuya Nakamura, Hiroshi Nakayama, Nobuaki Shimizu, Y. Matsuo, Yoshitaka Sekine
Publikováno v:
Journal of Urology. 206
Autor:
Yoshitaka Sekine, Yutaka Takezawa, Takahiro Syuto, Hiroshi Matsui, Nobuaki Shimizu, Toshiyuki Nakamura, Kazuhiro Suzuki, Sota Kurihara, Takeshi Miyao, Yoshiyuki Miyazawa, Masashi Nomura, Yasuhiro Shibata, Hiroshi Nakayama, Hidekazu Koike
Publikováno v:
The Prostate. 79:1457-1465
BACKGROUND Recent studies have shown that an early prostate-specific antigen (PSA) response to androgen receptor-targeting agents in metastatic castration-resistant prostate cancer (mCRPC) is associated with a better prognosis. We analyzed the early
Publikováno v:
Anticancer research. 40(9)
Background/aim The purpose of the present study was to clarify whether treatment with YM155, a novel small-molecule inhibitor of survivin, reversed cabazitaxel resistance in castration-resistant prostate cancer (CRPC). Materials and methods Cabazitax
Autor:
Daisuke Oka, Takeshi Miyao, Masanori Aoki, Seiji Arai, Yasuhiro Shibata, Akira Otsu, Hiroshi Matsui, Kazuhiro Suzuki, Hiroshi Nakayama, Yoshiyuki Miyazawa, Yoshitaka Sekine, Hidekazu Koike
Publikováno v:
Journal of Urology. 203
Autor:
Manabu Kamiyama, Kenichi Harada, Akito Ito, Hideyasu Matsuyama, Katsuyoshi Hashine, Go Kaneko, Tomohiko Ichikawa, Yutaka Sugiyama, Hiroaki Shiina, Takeshi Miyao, Hiroyuki Horikoshi, Atsushi Mizokami, Prostat-Bsi Investigators, Kenichi Nakajima, Satoru Takahashi
Publikováno v:
International Journal of Urology. 25(5):492-499
Objective: To present the study design and rationale of Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index, a prospective study aiming to determine the role of the bone scan index, the amount of bone metastasis, in